Silva: Clinical-Epidemiology Aspect of Inpatients With Moderate or Severe COVID-19 in a Brazilian Macroregion: Disease and Countermeasures [Ivermectin]

Clinical-Epidemiology Aspect of Inpatients With Moderate or Severe COVID-19 in a Brazilian Macroregion: Disease and Countermeasures

Silva et al., Frontiers in Cellular and Infection Microbiology, doi:10.3389/fcimb.2022.899702

Silva et al., Clinical-Epidemiology Aspect of Inpatients With Moderate or Severe COVID-19 in a Brazilian Macroregion:.., Frontiers in Cellular and Infection Microbiology, doi:10.3389/fcimb.2022.899702

May 2022 Source PDF

Twitter
Facebook

All Studies Meta

Retrospective 395 hospitalized patients in Brazil, showing mortality HR 0.59 for antiparasitic use, however there were only 8 patients treated and authors do not distinguish between albendazole and ivermectin.

Important missing comments or errors? Let us know.

risk of death, 32.3% lower, RR 0.68, p = 0.57, treatment 8, control 387, adjusted per study, odds ratio converted to relative risk, ivermectin or albendazole, multivariable, control prevalance approximated with overall prevalence.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Silva et al., 20 May 2022, retrospective, Brazil, peer-reviewed, mean age 58.4, 28 authors, study period 25 March, 2020 - 21 October, 2020.

Contact: pos-doc.rodrigues@uftm.edu.br.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Ivermectin All

Abstract: ORIGINAL RESEARCH published: 20 May 2022 doi: 10.3389/fcimb.2022.899702 Edited by: Rodrigo Ivo Santos, North Carolina State University, United States Reviewed by: Rafael Kroon Campos, University of Texas Medical Branch at Galveston, United States Adam Ronk, Battelle, United States *Correspondence: Wellington Francisco Rodrigues pos-doc.rodrigues@uftm.edu.br † These authors have contributed equally to this work Specialty section: This article was submitted to Clinical Microbiology, a section of the journal Frontiers in Cellular and Infection Microbiology Received: 19 March 2022 Accepted: 19 April 2022 Published: 20 May 2022 Citation: Silva BRO, Rodrigues WF, Abadia DGP, Alves da Silva DA, Andrade e Silva LE, Desidério CS, Farnesi-de-Assunção TS, Costa-Madeira JC, Barbosa RM, Bernardes e Borges AV, Hortolani Cunha ACC, Pereira LQ, Helmo FR, Lemes MR, Barbosa LM, Trevisan RO, Obata MMS, Bueno GF, Mundim FV, Oliveira-Scussel ACM, Monteiro IB, Ferreira YM, Machado GH, Ferreira-Paim K, Moraes-Souza H, da Silva MV, Rodrigues Júnior V and Oliveira CJF (2022) Clinical-Epidemiology Aspect of Inpatients With Moderate or Severe COVID-19 in a Brazilian Macroregion: Disease and Countermeasures. Front. Cell. Infect. Microbiol. 12:899702. doi: 10.3389/fcimb.2022.899702 Clinical-Epidemiology Aspect of Inpatients With Moderate or Severe COVID-19 in a Brazilian Macroregion: Disease and Countermeasures Bruna Raphaela Oliveira Silva 1†, Wellington Francisco Rodrigues 1*†, Daniela Gomes Pires Abadia 1, Djalma A. Alves da Silva 1, Leonardo E. Andrade e Silva 1, Chamberttan S. Desidério 1, Thais Soares Farnesi-de-Assunção 1, Juliana C. Costa-Madeira 1, Rafaela M. Barbosa 1, Anna V. Bernardes e Borges 1, Andrezza C. C. Hortolani Cunha 2, Loren Q. Pereira 3, Fernanda R. Helmo 1, Marcela Rezende Lemes 1, Laı́s M. Barbosa 1, Rafael O. Trevisan 1, Malu Mateus Santos Obata 1, Giovanna F. Bueno 1, Fabiano V. Mundim 1, Ana Carolina M. Oliveira-Scussel 1, Ivan B. Monteiro 4,5, Yulsef M. Ferreira 5, Guilherme H. Machado 6, Kennio Ferreira-Paim 1, Hélio Moraes-Souza 3, Marcos Vinicius da Silva 1, Virmondes Rodrigues Júnior 1 and Carlo José Freire Oliveira 1 1 Department of Immunology, Microbiology and Parasitology, Federal University of Triângulo Mineiro, Uberaba, Brazil, 2 Postgraduate Program in Physiological Sciences, Federal University of Triângulo Mineiro, Uberaba, Brazil, 3 Laboratory of Hematological Research of the Federal University of Triângulo Mineiro and Regional Blood Center of Uberaba - Hemominas Foundation, Uberaba, Brazil, 4 UNIMED São Domingos Hospital, Uberaba, MG, Brazil. José Alencar Gomes da Silva Regional Hospital, Uberaba, Brazil, 5 José Alencar Gomes da Silva Regional Hospital, Uberaba, Brazil, 6 Mário Palmério University Hospital, Uberaba, Brazil COVID-19, also known as coronavirus disease 2019, is an infectious viral disease caused by SARS-CoV-2, a novel coronavirus. Since its emergence, its epidemiology has been explored; however, for some regions of the world, COVID-19’s behavior, incidence, and impact remain unclear. In continental nations like Brazil, this lack of knowledge results in nonuniform control, prevention, and treatment measures, which can be controversial in some locations. This study aimed to describe the epidemiological proﬁle of patients with COVID-19 in the macroregion of Triâ ngulo Sul in the state of Minas Gerais (MG), Brazil. Between March 25 and October 21, 2020, data were collected and statistically analyzed..

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit